secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001213900-23-024937
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma reports FY2022 net loss $12.7M, cash $4.0M; advances AD04 regulatory meetings
--------------------------------------------------------------------------------

- Net loss $12.7M for FY2022 vs $19.4M in FY2021; cash and equivalents $4.0M.
- R&D expenses down 50% to $4.2M; G&A down 2% to $9.3M.
- ONWARD Phase 3: AD04 significantly reduced heavy drinking days in heavy drinkers; identified two target genotypes.
- Secured meetings with FDA, Swedish MPA, German BfArM in Q2 2023 for AD04 approval path.
- Option to sell Purnovate to Adovate; potential milestones up to $83M plus 19.9% equity stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/0001213900-23-024937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/ea176126-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-024937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer